Anchor Therapeutics, a Cambridge, MA-based pre-clinical stage drug discovery and development company, has held an initial closing of $10m in Series B financing.
The investment is being led by existing investors TVM Capital, HealthCare Ventures and the Novartis Option Fund.
The company is currently in discussions with additional investors interested in joining this Series B round.
Anchor Therapeutics is focused on developing peptide drug candidates, called pepducins, that modulate G protein coupled receptors (GPCRs), particularly those historically difficult to target using standard pharmaceutical approaches.
FinSMEs
20/08/2010